Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuhiro Yoshimura

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015
Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell CarcinomaTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
World Journal of Urology|March 1, 2021
A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancerYasuhide Miyoshi, Sohgo Tsutsumi, Masato Yasui, et al.
BJUI Compass|April 27, 2022
Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patientsYasuhide Miyoshi, Masato Yasui, Sohgo Ttsutsumi, et al.
Cancer Medicine|August 31, 2022
Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamideSaizo Fujmoto, Kazutoshi Fujita, Mitsuhisa Nishimoto, et al.
Hinyokika Kiyo. Acta Urologica Japonica|November 23, 2013
[A case of a nonseminomatous germ cell tumor responding to MEA therapy]Yasuharu Nagai, Takafumi Minami, Yoshitaka Itami, et al.
International Immunopharmacology|March 31, 2015
New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype allelesTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
Journal of Neuroendovascular Therapy|August 7, 2023
Safety and Efficacy of Prasugrel Administration in Emergent Endovascular Treatment for Intracranial Atherosclerotic DiseaseKatsunori Asai, Masaaki Taniguchi, Hajime Nakamura, et al.
Hinyokika Kiyo. Acta Urologica Japonica|June 12, 2012
[A case of primary urotherial carcinoma with glandular differentiation of the renal pelvis with high serum level of carbohydrate antigen 19-9 (CA19-9)]Yoshitaka Itami, Nobutaka Shimizu, Taiji Hayashi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|August 17, 2012
[A case of prostatic cancer with a low PSA level accompanied with cystic formation requiring differentiation from adenocarcinoma of the seminal vesicle]Yoshitaka Itami, Yasuharu Nagai, Yasuyuki Kobayashi, et al.
Journal of Endourology|September 30, 2005
Retroperitoneoscopic living related-donor nephrectomy: clinical outcomes of 50 consecutive cases and comparison with open donor nephrectomyKazuhiro Yoshimura, Shiro Takahara, Miyaji Kyakuno, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015
Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell CarcinomaTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
World Journal of Urology|March 1, 2021
A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancerYasuhide Miyoshi, Sohgo Tsutsumi, Masato Yasui, et al.
BJUI Compass|April 27, 2022
Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patientsYasuhide Miyoshi, Masato Yasui, Sohgo Ttsutsumi, et al.
Cancer Medicine|August 31, 2022
Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamideSaizo Fujmoto, Kazutoshi Fujita, Mitsuhisa Nishimoto, et al.
Hinyokika Kiyo. Acta Urologica Japonica|November 23, 2013
[A case of a nonseminomatous germ cell tumor responding to MEA therapy]Yasuharu Nagai, Takafumi Minami, Yoshitaka Itami, et al.
International Immunopharmacology|March 31, 2015
New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype allelesTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
Journal of Neuroendovascular Therapy|August 7, 2023
Safety and Efficacy of Prasugrel Administration in Emergent Endovascular Treatment for Intracranial Atherosclerotic DiseaseKatsunori Asai, Masaaki Taniguchi, Hajime Nakamura, et al.
Hinyokika Kiyo. Acta Urologica Japonica|June 12, 2012
[A case of primary urotherial carcinoma with glandular differentiation of the renal pelvis with high serum level of carbohydrate antigen 19-9 (CA19-9)]Yoshitaka Itami, Nobutaka Shimizu, Taiji Hayashi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|August 17, 2012
[A case of prostatic cancer with a low PSA level accompanied with cystic formation requiring differentiation from adenocarcinoma of the seminal vesicle]Yoshitaka Itami, Yasuharu Nagai, Yasuyuki Kobayashi, et al.
Journal of Endourology|September 30, 2005
Retroperitoneoscopic living related-donor nephrectomy: clinical outcomes of 50 consecutive cases and comparison with open donor nephrectomyKazuhiro Yoshimura, Shiro Takahara, Miyaji Kyakuno, et al.
Pageof 11